Piper Jaffray Remains Bullish on Horizon Pharma (HZNP) Despite Sell-Off; Says Business is Sustainable

Mizuho Securities Remains Bullish on Horizon Pharma (HZNP); Says Subpoena Appears Benign

March 1, 2016 7:01 AM EST

Mizuho Securities maintained a Buy rating on Horizon Pharma (NASDAQ: HZNP), and cut the price target to $34.00 (from $36.00), following the company's 4Q earnings report. HZNP reported a strong revenues of $244.5M and EPS of $0.63 vs. consensus estimates of $240.8M and $0.61. Mgmt indicated the... More

Horizon Pharma (HZNP) Filing Shows Subpoena Related to Patient Assistance Program

February 29, 2016 9:12 AM EST

Horizon Pharma's (NASDAQ: HZNP) 10K showed a subpoena related to its patient assistance program.

From the filing:

In November 2015, we received a subpoena from the U.S. Attorneys Office for the Southern District of New York requesting documents and... More

Horizon Pharma (HZNP) Tops Q4 EPS by 1c

February 29, 2016 7:01 AM EST

Horizon Pharma (NASDAQ: HZNP) reported Q4 EPS of $0.63, $0.01 better than the analyst estimate of $0.62. Revenue for the quarter came in at $244.5 million versus the consensus estimate of $240.92 million.

Orphan Business Unit: ACTIMMUNE sales of $28.1 million increased 25 percent compared to the fourth quarter of 2014. RAVICTI and BUPHENYL sales in the fourth quarter were $34.5 million and $5.6 million, respectively. The orphan commercial organization continues to drive awareness of ACTIMMUNE and RAVICTI among both... More

Trading Radar for 2/29: Curis (CRIS), Lumber Liquidators (LL), Netlist (NLST), TASER Int'l (TASR) Report

February 26, 2016 3:19 PM EST

The Trading Radar highlights key earnings and economic announcements for the next trading session:

Before Markets Open:

Earnings:

3D Systems (NYSE: DDD) - consensus EPS $0.03
AMC Entertainment (NYSE: AMC) - consensus EPS $0.40
Acadia Pharma (Nasdaq: ACAD) - consensus loss $0.38
Altisource Residential (NYSE: RESI) - consensus EPS $0.18
Ares Management (Nasdaq: ARES) - consensus EPS $0.29
Arqule (Nasdaq: ARQL) - consensus loss... More

Horizon Pharma (HZNP) Could Buy Back All Shares Over 5 Years, Squeeze Shorts - Guggenheim

February 26, 2016 7:02 AM EST

Guggenheim analyst, Louise Chen believes that Horizon Pharma (NASDAQ: HZNP) shares are range bound as the Street works through some overhangs (primary care business, generic competition for Vimovo, headline risks in healthcare). But the stock could be $40+ by year-end if the company successfully executes on its business objectives and the data for... More